Mutant sodium channel for tumor therapy

Bakhos A. Tannous*, Adam P. Christensen, Lisa Pike, Thomas Wurdinger, Katherine F. Perry, Okay Saydam, Andreas H. Jacobs, Jaime Garcia-Anoveros, Ralph Weissleder, Miguel Sena-Esteves, David P. Corey, Xandra O. Breakefield

*Corresponding author for this work

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Viral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein-Barr virus (HSV/ EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.

Original languageEnglish (US)
Pages (from-to)810-819
Number of pages10
JournalMolecular Therapy
Volume17
Issue number5
DOIs
StatePublished - Mar 4 2009

Fingerprint

Sodium Channels
Neoplasms
Therapeutics
Doxycycline
Human Herpesvirus 4
Sodium
Transcriptional Silencer Elements
Amiloride
Gap Junctions
Human Herpesvirus 1
Tetracycline
Nude Mice
Gene Expression
Mutation
Injections
Brain

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Tannous, B. A., Christensen, A. P., Pike, L., Wurdinger, T., Perry, K. F., Saydam, O., ... Breakefield, X. O. (2009). Mutant sodium channel for tumor therapy. Molecular Therapy, 17(5), 810-819. https://doi.org/10.1038/mt.2009.33
Tannous, Bakhos A. ; Christensen, Adam P. ; Pike, Lisa ; Wurdinger, Thomas ; Perry, Katherine F. ; Saydam, Okay ; Jacobs, Andreas H. ; Garcia-Anoveros, Jaime ; Weissleder, Ralph ; Sena-Esteves, Miguel ; Corey, David P. ; Breakefield, Xandra O. / Mutant sodium channel for tumor therapy. In: Molecular Therapy. 2009 ; Vol. 17, No. 5. pp. 810-819.
@article{3e156a5451d247718fe039f29da97c24,
title = "Mutant sodium channel for tumor therapy",
abstract = "Viral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein-Barr virus (HSV/ EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.",
author = "Tannous, {Bakhos A.} and Christensen, {Adam P.} and Lisa Pike and Thomas Wurdinger and Perry, {Katherine F.} and Okay Saydam and Jacobs, {Andreas H.} and Jaime Garcia-Anoveros and Ralph Weissleder and Miguel Sena-Esteves and Corey, {David P.} and Breakefield, {Xandra O.}",
year = "2009",
month = "3",
day = "4",
doi = "10.1038/mt.2009.33",
language = "English (US)",
volume = "17",
pages = "810--819",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

Tannous, BA, Christensen, AP, Pike, L, Wurdinger, T, Perry, KF, Saydam, O, Jacobs, AH, Garcia-Anoveros, J, Weissleder, R, Sena-Esteves, M, Corey, DP & Breakefield, XO 2009, 'Mutant sodium channel for tumor therapy', Molecular Therapy, vol. 17, no. 5, pp. 810-819. https://doi.org/10.1038/mt.2009.33

Mutant sodium channel for tumor therapy. / Tannous, Bakhos A.; Christensen, Adam P.; Pike, Lisa; Wurdinger, Thomas; Perry, Katherine F.; Saydam, Okay; Jacobs, Andreas H.; Garcia-Anoveros, Jaime; Weissleder, Ralph; Sena-Esteves, Miguel; Corey, David P.; Breakefield, Xandra O.

In: Molecular Therapy, Vol. 17, No. 5, 04.03.2009, p. 810-819.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mutant sodium channel for tumor therapy

AU - Tannous, Bakhos A.

AU - Christensen, Adam P.

AU - Pike, Lisa

AU - Wurdinger, Thomas

AU - Perry, Katherine F.

AU - Saydam, Okay

AU - Jacobs, Andreas H.

AU - Garcia-Anoveros, Jaime

AU - Weissleder, Ralph

AU - Sena-Esteves, Miguel

AU - Corey, David P.

AU - Breakefield, Xandra O.

PY - 2009/3/4

Y1 - 2009/3/4

N2 - Viral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein-Barr virus (HSV/ EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.

AB - Viral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein-Barr virus (HSV/ EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.

UR - http://www.scopus.com/inward/record.url?scp=67349163024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349163024&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.33

DO - 10.1038/mt.2009.33

M3 - Article

VL - 17

SP - 810

EP - 819

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -

Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O et al. Mutant sodium channel for tumor therapy. Molecular Therapy. 2009 Mar 4;17(5):810-819. https://doi.org/10.1038/mt.2009.33